One-year access to more than 500 world journals available in the system
-
http://medilib.ir
- Duration of Time : 365 Day
Price : 300$- Special Price : 100$
EULAR 75-year anniversary: commentaries on ARD papers from 50 years ago
Johannes WJ Bijlsma
doi : 10.1136/ard-2022-222584
October 2022 - Volume 81 - 10
Implementation of recommendations in rheumatic and musculoskeletal diseases: considerations for development and uptake
Estibaliz Loza, Loreto Carmona, Anthony Woolf, Bruno Fautrel, Delphine S Courvoisier, Suzanne Verstappen, Sella Aarrestad Provan, Annelies Boonen, Thea Vliet Vlieland, Francesca Marchiori, Tiina Jasinski, Kristien Van der Elst, Mwidimi Ndosi, Krysia Dziedzic, Jose Miguel Carrasco
doi : 10.1136/ard-2022-223016
Assessing acceptability and identifying barriers and facilitators to implementation of the EULAR recommendations for patient education in inflammatory arthritis: a mixed-methods study with rheumatology professionals in 23 European and Asian countries
Sarah E Bennett, Heidi A Zangi, Ingrid Larsson, Catherine Beauvais, Carina Boström, Andrea Domján, Yvonne van Eijk-Hustings, Kristien Van der Elst, Françoise Fayet, Ricardo J O Ferreira, Mie Fusama, Mariela Geneva-Popova, MarÃa del Carmen Herrero Manso, Kirsten Hoeper, Bethan Jones, Marja Leena Kukkurainen, Suet Kei Gladys Kwok, Patricia Minnock, Tiziana Nava, Jette Primdahl, Roopa Rawat, Matylda Sierakowska, Michaela Stoffer-Marx, Astrid van Tubergen, Mwidimi Ndosi
Effectiveness of TNF-inhibitors, abatacept, IL6-inhibitors and JAK-inhibitors in 31 846 patients with rheumatoid arthritis in 19 registers from the ‘JAK-pot’ collaboration
Kim Lauper, Michele Iudici, Denis Mongin, Sytske Anne Bergstra, Denis Choquette, Catalin Codreanu, René Cordtz, Diederik De Cock, Lene Dreyer, Ori Elkayam, Ellen-Margrethe Hauge, Doreen Huschek, Kimme L Hyrich, Florenzo Iannone, Nevsun Inanc, Lianne Kearsley-Fleet, Eirik Klami Kristianslund, Tore K Kvien, Burkhard F Leeb, Galina Lukina, Dan C Nordström, Karel Pavelka, Manuel Pombo-Suarez, Ziga Rotar, Maria Jose Santos, Anja Strangfeld, Patrick Verschueren, Delphine Sophie Courvoisier, Axel Finckh
Tumour necrosis factor inhibitor use during pregnancy is associated with increased birth weight of rheumatoid arthritis patients’ offspring
Hieronymus T W Smeele, Esther Röder, Annemarie G M G J Mulders, Eric A P Steegers, Radboud J E M Dolhain
doi : 10.1136/ard-2022-222679
Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis
Andreas Kerschbaumer, Zaïda Iasha Rivai, Josef S Smolen, Daniel Aletaha
Standardisation of ACPA tests: evaluation of a new candidate reference preparation
Lieve Van Hoovels, Lucy Studholme, Bert Vander Cruyssen, Daniela Sieghart, Carolien Bonroy, Eszter Nagy, Rille Pullerits, Sasa Ču�nik, Charlotte Dahle, Ingmar Heijnen, Luca Bernasconi, Farid Benkhadra, Laura Bogaert, Stefanie Van Den Bremt, Ann Van Liedekerke, Geert Vanheule, Johan Robbrecht, Claudine Wirth, Rüdiger Müller, Diego Kyburz, Christopher Sjöwall, Alf Kastbom, Rok Ješe, Boja Jovancevic, Emese Kiss, Peggy Jacques, Daniel Aletaha, Günter Steiner, Patrick Verschueren, Xavier Bossuyt
Longitudinal trajectories of fatigue in early RA: the role of inflammation, perceived disease impact and early treatment response
Michaël Doumen, Sofia Pazmino, Delphine Bertrand, Diederik De Cock, Johan Joly, René Westhovens, Patrick Verschueren
Treat-to-target dose reduction and withdrawal strategy of TNF inhibitors in psoriatic arthritis and axial spondyloarthritis: a randomised controlled non-inferiority trial
Celia AJ Michielsens, Nathan den Broeder, Frank HJ van den Hoogen, Elien AM Mahler, Steven Teerenstra, Désirée van der Heijde, Lise M Verhoef, Alfons A den Broeder
Keratinocyte-derived S100A9 modulates neutrophil infiltration and affects psoriasis-like skin and joint disease
Liliana F Mellor, Nuria Gago-Lopez, Latifa Bakiri, Felix N Schmidt, Björn Busse, Simon Rauber, Maria Jimenez, Diego MegÃas, Sergio Oterino-Sogo, Ricardo Sanchez-Prieto, Sergei Grivennikov, Xinzhu Pu, Julia Oxford, Andreas Ramming, Georg Schett, Erwin F Wagner
Cross-species transcriptome analysis for early detection and specific therapeutic targeting of human lupus nephritis
Eleni Frangou, Panagiotis Garantziotis, Maria Grigoriou, Aggelos Banos, Dionysis Nikolopoulos, Antigone Pieta, Stavros A Doumas, Antonis Fanouriakis, Aikaterini Hatzioannou, Theodora Manolakou, Themis Alissafi, Panayotis Verginis, Emmanouil Athanasiadis, Emmanouil Dermitzakis, George Bertsias, Anastasia Filia, Dimitrios T Boumpas
Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial
Noemie Jourde-Chiche, Nathalie Costedoat-Chalumeau, Karine Baumstarck, Anderson Loundou, Laurence Bouillet, Stéphane Burtey, Valérie Caudwell, Laurent Chiche, Lionel Couzi, Laurent Daniel, Christophe Deligny, Bertrand Dussol, Stanislas Faguer, Pierre Gobert, Guillaume Gondran, Antoine Huart, Aurélie Hummel, Emilie Kalbacher, Adexandre Karras, Marc Lambert, Véronique Le Guern, Ludivine Lebourg, Sandrine Loubière, Hélène Maillard-Lefebvre, François Maurier, Micheline Pha, Viviane Queyrel, Philippe Remy, Françoise Sarrot-Reynauld, David Verhelst, Eric Hachulla, Zahir Amoura, Eric Daugas
Hypomethylation of miR-17-92 cluster in lupus T cells and no significant role for genetic factors in the lupus-associated DNA methylation signature
Patrick Coit, Xiavan Roopnarinesingh, Lourdes Ortiz-Fernández, Kathleen McKinnon-Maksimowicz, Emily E Lewis, Joan T Merrill, W Joseph McCune, Jonathan D Wren, Amr H Sawalha
The effect of achieving serological remission on subsequent risk of relapse, end-stage renal disease and mortality in ANCA-associated vasculitis: a target trial emulation study
Gregory McDermott, Xiaoqing Fu, Claire Cook, Catherine Ahola, Brett Doliner, Jennifer Hanberg, John H Stone, Hyon K Choi, Yuqing Zhang, Zachary S Wallace
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case–control study
Léo Plaçais, Stéphane Dalle, Olivier Dereure, Sabiha Trabelsi, Sophie Dalac, Delphine Legoupil, Henri Montaudié, Jean-Philippe Arnault, Julie De Quatrebarbes, Philippe Saiag, Florence Brunet-Possenti, Thierry Lesimple, Eve Maubec, François Aubin, Florence Granel-Brocard, Jean-Jacques Grob, Pierre-Emmanuel Stoebner, Clara Allayous, Bastien Oriano, Caroline Dutriaux, Laurent Mortier, Céleste Lebbe
doi : 10.1136/ard-2022-222186
Gain-of-function mutations in ALPK1 cause an NF-κB-mediated autoinflammatory disease: functional assessment, clinical phenotyping and disease course of patients with ROSAH syndrome
Christina Torres Kozycki, Shilpa Kodati, Laryssa Huryn, Hongying Wang, Blake M Warner, Priyam Jani, Dima Hammoud, Mones S Abu-Asab, Yingyos Jittayasothorn, Mary J Mattapallil, Wanxia Li Tsai, Ehsan Ullah, Ping Zhou, Xiaoying Tian, Ariane Soldatos, Niki Moutsopoulos, Marie Kao-Hsieh, Theo Heller, Edward W Cowen, Chyi-Chia Richard Lee, Camilo Toro, Shelley Kalsi, Zohreh Khavandgar, Alan Baer, Margaret Beach, Debra Long Priel, Michele Nehrebecky, Sofia Rosenzweig, Tina Romeo, Natalie Deuitch, Laurie Brenchley, Eileen Pelayo, Wadih Zein, Nida Sen, Alexander H Yang, Gary Farley, David A Sweetser, Lauren Briere, Janine Yang, Fabiano de Oliveira Poswar, Ida Vanessa D Schwartz, Tamires Silva Alves, Perrine Dusser, Isabelle Koné-Paut, Isabelle Touitou, Salah Mohamed Titah, Petrus Martin van Hagen, Rogier T A van Wijck, Peter J van der Spek, Hiromi Yano, Andreas Benneche, Ellen M Apalset, Ragnhild Wivestad Jansson, Rachel R Caspi, Douglas Byron Kuhns, Massimo Gadina, Hidetoshi Takada, Hiroaki Ida, Ryuta Nishikomori, Elena Verrecchia, Eugenio Sangiorgi, Raffaele Manna, Brian P Brooks, Lucia Sobrin, Robert B Hufnagel, David Beck, Feng Shao, Amanda K Ombrello, Ivona Aksentijevich, Daniel L Kastner
NOD/RIPK2 signalling pathway contributes to osteoarthritis susceptibility
Michael J Jurynec, Catherine M Gavile, Matthew Honeggar, Ying Ma, Shivakumar R Veerabhadraiah, Kendra A Novak, Kazuyuki Hoshijima, Nikolas H Kazmers, David J Grunwald
Livedo racemosa and thrombotic vasculitides of scalp in systemic lupus erythematosus
Jui-Yun Lee, Chang-Youh Tsai, Hsien-Tzung Liao
doi : 10.1136/ard-2022-222672
Chronic glucocorticoid maintenance treatment is associated with the risk of SARS-CoV-2 infection in patients with systemic lupus erythematosus who received vaccination
Giuseppe A Ramirez, Lorenza Maria Argolini, Tommaso Schioppo, Savino Sciascia, Luca Moroni, Gabriella Moroni, Renato Alberto Sinico, Grazia Bonelli, Federico Alberici, Federica Mescia, Francesco Tamborini, Paolo Miraglia, Chiara Bellocchi, Lorenzo Beretta, Dario Roccatello, Enrica Paola Bozzolo, Roberto Caporali, Maria Gerosa, Lorenzo Dagna
doi : 10.1136/ard-2022-222832
Oral antiviral treatment in patients with systemic rheumatic disease at risk for development of severe COVID-19: a case series
George E Fragoulis, Christos Koutsianas, Kalliopi Fragiadaki, Ilias Mariolis, Stylianos Panopoulos, Christina Tsalapaki, Maria Pappa, Theodoros Dimitroulas, Maria G Tektonidou, Dimitrios Vassilopoulos, Petros P Sfikakis
Guselkumab for treating immune checkpoint inhibitor-induced psoriatic arthritis
Koichi Takeda, Noriko Yanagitani
Genetically proxied IL-6 receptor inhibition and risk of polymyalgia rheumatica
Sizheng Steven Zhao, Dipender Gill
Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience
Asim Khan, Alice Cole, Naveen Bhadauria, Munzir El-Hassan, Daud Abdulla, Thomas Axon, Zozik Fattah, Jessica J Manson, Jeronimo Moreno-Cuesta, Dev Mukerjee
Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al
Ioana Andreica, David Kiefer, Guenther A Rezniczek, Robert Jast, Bjoern Buehring, Uta Kiltz, Xenofon Baraliakos, Juergen Braun
COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs
Khalil Ansarin, Ali Taghizadieh, Saeid Safiri, Aida Malek Mahdavi, Shirin Ranjbar, Soheil Teymouri, Masoud Ahangari Maleki, Alireza Khabbazi
COVID-19 Global Rheumatology Alliance Registry, anti-IL-6 therapy, shared decision-making and patient outcomes. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Compassionate use of tocilizumab in severe COVID-19 with hyperinflammation prior to advent of clinical trials – a real-world district general hospital experience’ by Khan et al, ‘Comment on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry’ by Gianfrancesco M et al’ by Andreica et al and ‘COVID-19 outcomes in patients with systemic autoimmune diseases treated with immunomodulatory drugs’ by Ansarin et al
Milena Gianfrancesco, Kimme L Hyrich, Jinoos Yazdany, Pedro M Machado, Philip C Robinson
Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5-positive dermatomyositis-associated rapidly progressive interstitial lung diseases: a challenge for the future
Yukai Wang, Guangzhou Du, Guohong Zhang, Marco Matucci-Cerinic, Daniel E Furst
Response to: ‘Similarities and differences between severe COVID-19 pneumonia and anti-MDA-5 positive dermatomyositis associated rapidly progressive interstitial lung diseases: a challenge for the future’ by Wang et al
Janine A Lamb, Spyridon Megremis, Hector Chinoy
Correspondence on ‘Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al
Leo Buckley
Response to: ‘Correspondence on ‘Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case–control study’ by Potere et al’ by Buckley
Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti
Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation—an open-label cohort study’ by Della-Torre et al
Chao Cheng, Fangjie Zhang
Impact of sarilumab on mechanical ventilation in patients with COVID-19. Response to: ‘Correspondence on: ‘Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation–an open-label cohort study’ by Della-Torre et al’ by Cheng and Zhang
Emanuel Della-Torre, Giovanni Landoni, Alberto Zangrillo, Lorenzo Dagna
Colchicine treatment in community healthcare setting to prevent severe COVID-19
Emanuel Della-Torre, Giuseppe A Ramirez, Lorenzo Dagna, Moreno Tresoldi
Anti-inflammatory action of colchicine in hospitalised patients with COVID-19. Response to: ‘Colchicine treatment in community healthcare setting to prevent severe COVID-19’ by Della-Torre et al
Silvia Piantoni, Enrico Colombo, Roberto Furloni, Laura Andreoli, Antonio Brucato, Massimo Imazio, Paolo Airó, Mirko Scarsi
Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic
Alireza Khabbazi, Hadiseh Kavandi, Roghayeh Paribanaem, Raha Khabbazi, Aida Malek Mahdavi
Education and treatment adherence during the COVID-19 pandemic. Response to: ‘Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic’ by Khabbazi et al
Rita Angélica Pineda-Sic, Griselda Serna-Peña, Jesus Alberto Cardenas-de la Garza, Sergio A Torres-Castillo, Dionicio Angel Galarza-Delgado, Diana Elsa Flores-Alvarado
High dosage of methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to tocilizumab
Edoardo Conticini, Federico Franchi, David Bennett, Serafina Valente, Maria A Mazzei, Elena Bargagli, Luca Volterrani, Sabino Scolletta, Bruno Frediani
Response to: ‘High dosage of Methylprednisolone as a rescue, second-line treatment in COVID-19 patients who failed to respond to Tocilizumab’ by Conticini et al
Sofia Ramiro, Rémy Mostard, Robert BM Landewé
Tocilizumab for the treatment of polyarteritis nodosa: a systematic literature review. Correspondence on ‘Tofacitinib for polyarteritis nodosa: a tailored therapy’ by Rimar et al
Mitsuhiro Akiyama, Yuko Kaneko, Tsutomu Takeuchi
Response to: ‘Tofacitinib for the treatment of polyarteritis nodosa: a literature review’. Correspondence on ‘Tofacitinib for polyarteritis nodosa: a tailored therapy’ by Rimar et al
Doron Rimar, Abid Awisat, Lisa Kaly, Gleb Slobodin, Itzhak Rosner, Michael Rozenbaum, Shira Ginsberg, Elina Starosvetsky, Ayelet Alpert, Shai Shen-Orr
Correspondence to: ‘Combination of human umbilical cord mesenchymal (stromal) stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis’
Kevin Sheng-Kai Ma, Li-Tzu Wang, Shin-Yi Tsai
Response to: ‘Correspondence to: ‘Combination of human umbilical cord mesenchymal stem cell transplantation with IFN-γ treatment synergistically improves the clinical outcomes of patients with rheumatoid arthritis’’ by Ma et al
Yi Yang, Xiao He, Mengwei Yao, Wei Xing, Luoquan Ao, Joseph A Bellanti, Song Guo Zheng, Xiang Xu
Tapering antirheumatic drugs in a resource-poor setting: real-world evidence
Muhammad Haroon, Zara Khan, Maryam Aamer
Response to: ‘Tapering antirheumatic drugs in a resource-poor setting: real-world evidence’ by Haroon et al
Elise van Mulligen, Pascal H P de Jong
Imaging in immune checkpoint inhibitor-induced polymyalgia rheumatica
Kornelis S M van der Geest, Maria Sandovici, Abraham Rutgers, T Jeroen N Hiltermann, Sjoukje F Oosting, Riemer H J A Slart, Elisabeth Brouwer
Correction: Granulocyte colony stimulating factor exacerbates antineutrophil cytoplasmic antibody vasculitis
